LuminaCare Solutions Presenting at “FAID 2016” Symposium Quick-Fire Start-up Pitches on February 9-10, 2016

“FAID 2016” Symposium Will Include Quick-Fire Start-up Pitches as Part of Its February 9-10, 2016, Program

Event will showcase French and American science-and-technology innovations and foster transatlantic collaborations in the life sciences.


BOSTON & PARIS–(BUSINESS WIRE)–Organizers announced today that there will be 2 pitch sessions at “French-American Innovation Days (FAID) 2016”, to be held on Tuesday and Wednesday, February 9 and 10, 2016, at the MIT Media Lab, 75 Amherst Street, Cambridge, Mass.

In alphabetical order, FAID 2016 companies to pitch will include; Ad Scientiam, Admetsys, Ariana Pharma, Axenis, Bioserenity, Ceeable, Curoverse, Eligo Bioscience, Enterome Bioscience, Exosome Diagnostics, LuminaCare Solutions, MAAT Pharma, Metafora, MTAnalytics, Neolys Diagnostic, NovaDiscovery, Osseomatrix, RxRevu, VoyagerMed and more to come. These companies will showcase their latest innovations and have the opportunity to attract their next partners.

The two-day event is focusing on the latest developments in Precision Medicine. It will bring together leading experts in the field to explore how these developments impact clinical research. The Symposium is also expected to facilitate research and development partnerships among researchers, emerging and established companies, business development executives and investors in the United States and France. The FAID symposium’s organizers are: The Office for Science and Technology of the Embassy of France in the United States in Boston; and, GLOBAL CARE Initiative.

Sponsorships opportunities are available; please contact GLOBAL CARE Initiative at


The Office for Science and Technology of the Embassy of France in the United-States
The Office for Science and Technology is a team of professors, senior researchers and engineers, in Washington D.C., in Boston, MA, and five other locations in the United States. Its mission is to promote bilateral partnerships in science, technology and innovation. It has been organizing the FAID conference in Boston since 2002.

GLOBAL CARE Initiative (Based in Paris and Lyon)
GLOBAL CARE Initiative is a consortium of five Carnot Human Health Institutes that covers four therapeutic fields in human health: cancer (solid tumors and lymphoma), vision and audition diseases and rehabilitation, infectious diseases and central nervous system diseases. The consortium brings together 2,500 researchers and a wide array of technical assets and expertise.

Ronald Trahan Associates Inc.
Ronald Trahan, President, , +1-508-359-4005, x108

LuminaCare Solutions One of MM&M Top 40 Healthcare Transformers

The Top 40 Healthcare Transformers

Change within a set-in-its-ways industry can be scary—that is, unless you”ve got the will and bravado to tackle it head-on. Here are the 40 inventors, ­strategists, advocates and wonks who are challenging, disrupting and otherwise transforming the healthcare business

David Howe – CEO LuminaCare Solutions
We”ve come far in our treatment of infections—yet when an individual contracts a stubborn one, the path to the right medication remains slow. “Patients are still dependent on culture methods, and timing is critical for a serious infection,” Howe says. To decrease that time lapse, improve outcomes and knock down costs, LuminaCare has devised a cloud-based predictive analytics platform that helps practitioners make better, faster decisions. According to Howe, the company”s models help point doctors toward the right antibacterial treatment within 24 hours, a buy cheap cialis online duration that has been shown to reduce hospital stays by at least 40%.
For now, LuminaCare”s challenge is to bring together all the players—pharmaceutical and diagnostic companies as well as hospitals—to make its model work. But in the years and months ahead, it hopes to expand its therapeutic slate. “We”re hoping to work with tuberculosis patients,” Howe says. “We”re considering ways we can work with pharmaceutical companies to create new antibiotic formulas.” —Sarah Mahoney

LuminaCare Solutions Selected as Innovative Startup in PM360’s Innovator Issue

Innovators 2015: Startups

Feature Articles by on December 15th, 2015 PM360’s Innovations Issue, established four years ago, serves as a comprehensive guide to our readers, providing a glimpse at the year’s most cutting-edge: Companies, Divisions, Startups, Products, Services and Strategies.

LuminaCare Solutions

David Howe, CEO and Co-Founder

Treating patients with infectious disease is difficult for physicians. Currently, one out of every two hospitalized patients is taking antibiotics with about half of the patients on antibiotics taking two or more antibiotics. Nearly 80% of U.S. hospitals prescribe inappropriate or redundant antibiotic combinations. The overuse of antibiotics in hospitals has contributed to increases in prevalence of drug-resistant bacterial infections after surgeries and chemotherapy with 50% of infections after surgery and 25% of infections after chemotherapy resistant to standard antibiotics. LuminaCare Solutions, founded in 2013, develops predictive analytics to reduce the time for selecting appropriate antibiotic treatments. The company’s precision medicine product and proprietary algorithms will provide physicians with a tool that integrates new bacterial diagnostic tools, drug information and patient information all in a cloud-based application. The algorithms use patient characteristics, identified bacteria and drug information to personalize the treatment to the patient, rapidly determine whether the bacteria are susceptible to the treatment and predict patient outcome. Meanwhile, the product will decrease the time required to discover the appropriate antibiotic treatment from two or more days to less than eight hours. This not only reduces the severity of the illness, but the length of hospital stay by two or more days. Currently, the company is developing predictive analytics for tuberculosis, pneumonia and other respiratory infections in patients with COPD and asthma and will start trials to demonstrate outcome improvement in patients in 2016.

Read more